Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis

被引:5
|
作者
Bai, Yuping [1 ]
He, Tingting [1 ]
Zhang, Liyan [2 ]
Liu, Qianqian [1 ]
Yang, Jing [1 ]
Zhao, Ziru [1 ]
Yang, Kehu [3 ]
Zhang, Min [4 ]
机构
[1] Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China
[2] Hebei Cangzhou Hosp Integrated Tradit Chinese & W, Dept Pathol, Cangzhou, Peoples R China
[3] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China
[4] Gansu Prov Hosp, Dept Pathol, Lanzhou, Peoples R China
来源
BMJ OPEN | 2022年 / 12卷 / 09期
基金
中国国家自然科学基金;
关键词
lymphoma; immunology; haematology; PREDICTS POOR-PROGNOSIS; TUMOR MICROENVIRONMENT; EXPRESSION; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; IMPACT;
D O I
10.1136/bmjopen-2021-060659
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3(+)) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results. Design Systematic review and meta-analysis. Data sources We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021. Eligibility criteria We included studies that analysed the prognostic significance of FOXP3(+) Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis. Data extraction and synthesis We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value. Results Fourteen eligible studies were identified. FOXP3(+) Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3(+) Treg expression (p(interaction)<0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3(+) Tregs was associated with better OS in all populations and in Asians when FOXP3(+) Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42). Conclusions Approaches to measuring FOXP3(+) Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3(+) Tregs in DLBCL. FOXP3(+) Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3(+) Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis☆
    Farooqi, Hanzala Ahmed
    Ullah, Muhammad Saffi
    Raza, Ahmed
    Sadiq, Zain
    Shaikh, Wardah Ali
    Muhammad, Rahmah
    Hussain, Muhammad Shoaib
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
  • [32] Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
    Ren Yuan-Rong
    Jin Yong-Dong
    Zhang Zhi-Hui
    Li Li
    Wu Ping
    中华医学杂志英文版, 2015, 128 (03) : 378 - 383
  • [33] R-CHOP compared to R-CHOP plus X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis
    Pasvolsky, Oren
    Rozental, Alon
    Raanani, Pia
    Gafter-Gvili, Anat
    Gurion, Ronit
    ACTA ONCOLOGICA, 2021, 60 (06) : 744 - 749
  • [34] Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis
    Qin, Wenqiong
    Yuan, Qiang
    Wu, Jingkui
    Yu, Haonan
    Wang, Ying
    Chen, Qiusong
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 358 - 366
  • [35] Prognostic Value of Tumor-Infiltrating FoxP3+ T Cells in Gastrointestinal Cancers: A Meta Analysis
    Huang, Yong
    Liao, Huaiwei
    Zhang, Yong
    Yuan, Rongfa
    Wang, Fengmei
    Gao, Yingtang
    Wang, Peng
    Du, Zhi
    PLOS ONE, 2014, 9 (05):
  • [36] Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports
    Sun, Hui-Ling
    Pan, Yu-Qin
    He, Bang-Shun
    Nie, Zhen-Lin
    Lin, Kang
    Peng, Hong-Xin
    Cho, William C.
    Wang, Shu-Kui
    ONCOTARGETS AND THERAPY, 2016, 9 : 3017 - 3023
  • [37] Dissecting the Regulatory Microenvironment of a Large Animal Model of Non-Hodgkin Lymphoma: Evidence of a Negative Prognostic Impact of FOXP3+ T Cells in Canine B Cell Lymphoma
    Pinheiro, Dammy
    Chang, Yu-Mei
    Bryant, Hannah
    Sziadovits, Balazs
    Daiessandri, Tim
    Davison, Lucy J.
    Yallop, Elizabeth
    Mills, Emily
    Leo, Chiara
    Lara, Ana
    Stell, Anneliese
    Polton, Gerry
    Garden, Oliver A.
    PLOS ONE, 2014, 9 (08):
  • [38] Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
    Ren, Yuan-Rong
    Jin, Yong-Dong
    Zhang, Zhi-Hui
    Li, Li
    Wu, Ping
    CHINESE MEDICAL JOURNAL, 2015, 128 (03) : 378 - 383
  • [39] Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area
    Hosoda, Yuzuru
    Hino, Norihiko
    Motokura, Toru
    YONAGO ACTA MEDICA, 2018, 61 (01) : 58 - 65
  • [40] Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma
    Ke, Xiaoyan
    Wang, Jing
    Gao, Zifen
    Zhao, Lingzhi
    Li, Min
    Jing, Hongmei
    Wang, Jijun
    Zhao, Wei
    Gilbert, Heather
    Yang, Xiao-Feng
    BLOOD CELLS MOLECULES AND DISEASES, 2010, 44 (01) : 55 - 61